Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGBP-248
- Development stage
- Preclinical
- Lead developer
- Regen BioPharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intra-arterial, Intratumoral
01
Overview
RGBP-248 is a gene-silencing nucleic acid therapeutic developed by Regen BioPharma that utilizes RNA interference (RNAi) to target the BORIS (Brother of the Regulator of Imprinted Sites) gene, also known as CTCFL. BORIS is a cancer-testis antigen typically restricted to germ cells but aberrantly expressed in various malignancies, where it promotes cancer stem cell survival and cellular immortality via telomerase induction. By silencing BORIS expression, RGBP-248 is designed to specifically eliminate cancer stem cells that are often resistant to standard chemotherapy. The drug is intended for local delivery, including via transcatheter arterial chemoembolization (TACE) for liver cancer, and has shown preclinical efficacy in breast and colon cancer models. Regen BioPharma holds US Patent #8,263,571 covering specific therapeutic agents that gene silence BORIS.
- Other names
- BORIS gene silencing therapyCTCFL-targeting RNAiBORIS-molecular targeting-cancer
02
Targets
NR2F6 (Nuclear receptor subfamily 2 group F member 6)
Beyond the preview
Go deeper on RGBP-248.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGBP-248.